【Product for Licensing】siRNA Therapeutics Targeting AGT for Hypertension

siRNA products targeting angiotensinogen (AGT) are an innovative therapeutic approach specifically designed for the treatment of hypertension.

The global siRNA market was valued at $1.6 billion in 2023 and is expected to reach $4.59 billion by 2031, with an anticipated compound annual growth rate (CAGR) of 6.1% from 2024 to 2031. In this field, Alnylam is a pioneer and maintains a leading advantage in multiple targets and organ-specific delivery. Alnylam leads the development of siRNA therapies in common disease areas, including PCSK9 siRNA for hyperlipidemia and AGT siRNA for hypertension.

On July 24, 2023, Roche announced a partnership agreement with Alnylam to co-develop the latter’s AGT siRNA therapy, Zilebesiran, for the treatment of hypertensive patients at high cardiovascular risk. According to the agreement, Roche paid a $310 million upfront payment, as well as milestone payments and sales royalties. In the U.S. market, Roche and Alnylam are jointly responsible for commercialization, sharing rights equally. Outside the U.S., Roche is responsible for commercialization, with Alnylam receiving sales royalties. The total deal value is up to $2.8 billion.

On December 27, 2023, a strategic cooperation was reached among Chinese biotech companies to jointly develop siRNA drugs targeting AGT for the treatment of hypertension.

There are at least nine AGT-targeting siRNA drugs in development globally, with the most advanced being Zilebesiran, co-developed by Roche/Alnylam, which has reached the primary endpoint in Phase II clinical trials, showing a clinically significant reduction in 24-hour average systolic blood pressure by the third month.

siRNA products targeting AGT have tremendous potential in the global hypertension treatment market. As technology matures and partnerships are authorized among multiple pharmaceutical companies, the level of attention and competitiveness in this field is continuously increasing.

Currently, we have an AGT targeting siRNA, with big potential, looking for licensing partners.

If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap. Many thanks!~